Morgan Stanley Metacrine, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	SELL	$0.36 - $0.63 $4,377 - $7,661	-12,161 Reduced 96.05%	500 $0
Q2 2022 Aug 15, 2022	SELL	$0.36 - $0.63 $4,377 - $7,661	-12,161 Reduced 96.05%	500 $0
Q1 2022 Oct 27, 2022	BUY	$0.43 - $0.7 $5,229 - $8,512	12,161 Added 2432.2%	12,661 $8,000
Q1 2022 May 13, 2022	SELL	$0.43 - $0.7 $18,436 - $30,012	-42,875 Reduced 77.2%	12,661 $8,000
Q4 2021 Feb 14, 2022	BUY	$0.64 - $3.83 $26,389 - $157,922	41,233 Added 288.28%	55,536 $38,000
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $37,330 - $54,923	14,303 New	14,303 $49,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.